Searchable abstracts of presentations at key conferences on calcified tissues

ba0006p134 | (1) | ICCBH2017

Improvement in spinal involvement with zoledronic acid in pediatric patients with chronic recurrent multifocal osteomyelitis: a case series

Robinson Marie-Eve , Sbrocchi Anne Marie , Scuccimarri Rosie

Background: Chronic recurrent multifocal osteomyelitis (CRMO) is a rare inflammatory bone disease characterized by chronic non-infectious osteomyelitis. Spinal involvement has been reported in up to 26% of patients (1). Three studies evaluated the effect of Pamidronate (PAM) on spinal lesions in pediatric patients with CRMO (1, 2, 3) and showed partial or complete resolution of vertebral hyperintensities on MRI (1). However, the effect of Zoledronic acid (ZOL) in pediatric pat...

ba0007oc9 | (1) | ICCBH2019

Efficacy and safety of intravenous zoledronic acid for the treatment of pediatric glucocorticoid-induced osteoporosis: An international, randomized placebo-controlled trial

Ward Leanne M , Alos Nathalie , Cabral David A , Rodd Celia , Sbrocchi Anne Marie , Padidela Raja , Shaw Nick , Kostik Mikhail , Alexeeva Ekaterina , Thandrayen Kebashni , Aftring Paul , Choudhury Anup , Sunkara Gangadhar , Sayyed Sarfaraz , Munns Craig F.

Objectives: We evaluated the efficacy and safety of intravenous zoledronic acid (IV ZA) in children with glucocorticoid-induced osteoporosis (GIOP) through a randomized, placebo (PBO)-controlled trial.Methods: In this multi-national Phase 3 trial (NCT00799266), children 5–17 years of age with GIOP and low-trauma vertebral fractures (VF) were randomized 1:1 to IV ZA 0.05 mg/kg or IV PBO every six months for one year. Changes in lumbar spine areal bon...